Uni-Tübingen

11/16/2018

New Research Training Group "cGMP: From Bedside to Bench"

The newly approved GRK 2381 investigates new therapeutic options for established cGMP-modulating drugs

The DFG (Deutsche Forschungsgemeinschaft) will fund the new Research Training Group GRK 2381 "cGMP: From Bedside to Bench" at the University of Tübingen. The GRK 2381 will be coordinated by IFIB professor Robert Feil.

PhD students will be trained in the investigation of the second messenger cGMP (cyclic guanosine monophosphate). The Research Training Group (RTG) at the University of Tübingen will collaborate with partners in Boston to translate clinical experience with cGMP-modulating drugs “back” from “bedside to bench”. Each doctoral student will be co-mentored by a principal investigator in Boston who works on a related topic and she/he will visit the partner laboratory for a period of three months. Using state-of-the-art techniques and transgenic mouse models (developed by members of the RTG) fellows will gain critical new insights into cGMP’s role in cancer, cardiovascular diseases, and neurological disorders.

Further information:

Attempto Online (German)

 

Contact information:

Prof. Dr. Robert Feil (Speaker of GRK 2381)
Interfakultäres Institut für Biochemie (IFIB)
Hoppe-Seyler-Str. 4
72076 Tübingen
robert.feilspam prevention@uni-tuebingen.de

Back